NascaCell Technologies AG
NascaCell Technologies AG receives additional funding from the BioChance Plus program
NascaCell Technologies AG / Miscellaneous Release of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer / publisher is solely responsible for the content of this announcement. ---------------------------------------------------------------------- Munich, July 17, 2007 – NascaCell Technologies AG, today announced that it has received approval of additional funds to extend and broaden its efforts in the PADDION project which was started in the beginning of 2005. NascaCell will receive up to € 397.000 additional financial support from the German Federal Ministry of Education and Research (BmBF) in the course of this BioChance Plus program. The additional funds reflect additional work packages in this grant program and allow to include NascaCell's MicrobodyTM technology in the research program. PADDION focuses on the validation of potential targets useful for the development of novel anti-cancer therapies aimed at the inhibition of angiogenesis. This formation of new blood vessels is a crucial process for tumor growth. NascaCell and its partner PSF Biotech AG apply innovative aptamer, protein production and crystallisation technologies to validate candidate targets in cell culture models. MicrobodiesTM are now included as additional technology that can provide high quality leads for therapeutic developments. 'The decision of the national agency to increase NascaCell's funding is a great acknowledgement of the consortiums work done so far,' said Dr. Michael Blind, CSO of NascaCell. 'We are also very excited that we are now able to include our MicrobodyTM technology to develop new active agents that might serve as starting points for drug development programs in the future.' About NascaCell Technologies AG – www.nascacell.com NascaCell Technologies AG, based in Munich, is a global leading provider of a new generation of biomolecules. With the innovative Aptamer and MicrobodyTM technologies, the company supports customers in the target validation and drug discovery R&D areas. NascaCell also develops a line of products and drug development candidates based on the MicrobodyTM technology. About PSF biotech – www.psf-ag.com PSF biotech 'the protein structure factoryTM' offers unique resources for structure-aided drug discovery. The Berlin-based company is driven by an outstanding team of leading figures in genomics, structural biology and pharmacology. Knowing the 3D-structure of a protein target, the mechanism of agonism and antagonism can be understood; specific binders can be identified and subsequently modified to yield high quality lead candidates for new drugs. PSF offers a broad range of services centered on structural target validation and lead optimisation to shorten the time to market substantially, to save costs per drug and reduce the rate of failure. Contact: NascaCell Technologies AG InvestorPress GmbH Dr. Michael Blind Georg Breu Chief Scientific Officer Phone: +49(0)89 55 96 98 75 Phone: +49 (0)89-54 72 72-0 info@investorpress.de m.blind@nascacell.de DGAP 17.07.2007 ----------------------------------------------------------------------
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden